Endurance (Cayman) Ltd Svf Sells 12,844 Shares of Vir Biotechnology (NASDAQ:VIR) Stock

Vir Biotechnology, Inc. (NASDAQ:VIR) major shareholder Endurance (Cayman) Ltd Svf sold 12,844 shares of the firm’s stock in a transaction dated Thursday, October 16th. The shares were sold at an average price of $6.10, for a total transaction of $78,348.40. Following the sale, the insider directly owned 15,340,494 shares in the company, valued at approximately $93,577,013.40. The trade was a 0.08% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Large shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Endurance (Cayman) Ltd Svf also recently made the following trade(s):

• On Wednesday, October 15th, Endurance (Cayman) Ltd Svf sold 16,671 shares of Vir Biotechnology stock. The shares were sold at an average price of $6.07, for a total transaction of $101,192.97.
• On Friday, October 10th, Endurance (Cayman) Ltd Svf sold 2,300 shares of Vir Biotechnology stock. The stock was sold at an average price of $6.08, for a total transaction of $13,984.00.
• On Thursday, October 9th, Endurance (Cayman) Ltd Svf sold 249,060 shares of Vir Biotechnology stock. The stock was sold at an average price of $6.14, for a total transaction of $1,529,228.40.
• On Wednesday, October 8th, Endurance (Cayman) Ltd Svf sold 466,242 shares of Vir Biotechnology stock. The shares were sold at an average price of $6.05, for a total value of $2,820,764.10.
• On Tuesday, October 7th, Endurance (Cayman) Ltd Svf sold 72,133 shares of Vir Biotechnology stock. The stock was sold at an average price of $5.60, for a total value of $403,944.80.
• On Monday, October 6th, Endurance (Cayman) Ltd Svf sold 73,955 shares of Vir Biotechnology stock. The shares were sold at an average price of $5.69, for a total value of $420,803.95.
• On Friday, October 3rd, Endurance (Cayman) Ltd Svf sold 450,342 shares of Vir Biotechnology stock. The shares were sold at an average price of $5.56, for a total value of $2,503,901.52.

Vir Biotechnology Stock Performance

Shares of NASDAQ:VIR opened at $5.78 on Friday. The stock’s 50-day simple moving average is $5.16 and its two-hundred day simple moving average is $5.27. The stock has a market capitalization of $802.96 million, a price-to-earnings ratio of -1.45 and a beta of 1.27. Vir Biotechnology, Inc. has a 52-week low of $4.16 and a 52-week high of $14.45.

Vir Biotechnology (NASDAQ:VIR) last issued its quarterly earnings data on Wednesday, August 6th. The company reported ($0.80) earnings per share for the quarter, missing the consensus estimate of ($0.72) by ($0.08). The business had revenue of $1.21 million during the quarter, compared to the consensus estimate of $2.38 million. Vir Biotechnology had a negative return on equity of 50.22% and a negative net margin of 2,895.94%.Vir Biotechnology’s revenue for the quarter was down 60.5% on a year-over-year basis. During the same quarter last year, the company earned ($1.02) EPS. As a group, equities analysts forecast that Vir Biotechnology, Inc. will post -3.92 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Vir Biotechnology

Several large investors have recently made changes to their positions in VIR. ARCH Venture Management LLC purchased a new stake in shares of Vir Biotechnology during the second quarter worth about $65,100,000. Nordea Investment Management AB boosted its stake in Vir Biotechnology by 403.7% in the 2nd quarter. Nordea Investment Management AB now owns 704,377 shares of the company’s stock worth $3,677,000 after purchasing an additional 564,537 shares during the period. Clarius Group LLC grew its holdings in Vir Biotechnology by 979.7% during the 2nd quarter. Clarius Group LLC now owns 617,535 shares of the company’s stock valued at $3,112,000 after buying an additional 560,342 shares in the last quarter. Ensign Peak Advisors Inc raised its position in shares of Vir Biotechnology by 812.7% during the second quarter. Ensign Peak Advisors Inc now owns 582,981 shares of the company’s stock valued at $2,938,000 after buying an additional 519,107 shares during the last quarter. Finally, Nuveen LLC purchased a new position in shares of Vir Biotechnology in the first quarter worth $2,324,000. 65.32% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Vir Biotechnology in a research report on Tuesday, October 14th. HC Wainwright reissued a “buy” rating and set a $15.00 price target on shares of Vir Biotechnology in a report on Monday, September 15th. Raymond James Financial assumed coverage on Vir Biotechnology in a research note on Friday, July 11th. They issued an “outperform” rating on the stock. Evercore ISI began coverage on Vir Biotechnology in a research report on Wednesday, September 3rd. They set an “outperform” rating and a $12.00 price objective on the stock. Finally, Bank of America upgraded Vir Biotechnology from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $12.00 to $14.00 in a research note on Wednesday, August 27th. Nine investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $17.30.

About Vir Biotechnology

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).